GlassScriptPhysician profile
Harvey H Wolf
NPI 1215998760
$3,338.52
in general payments reported to CMS, 2019-2025
33 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $682 · 2021: $833 · 2022: $49.65 · 2023: $95.74 · 2024: $165 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $752.02 | 2019-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $222.27 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Pfizer INC. | $185.84 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $178.17 | 2019 | |
| Abbvie INC. | $165.61 | 2021-2025 | |
| Esperion Therapeutics, INC. | $163.84 | 2020-2021 | |
| Novo Nordisk INC | $156.33 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $138.67 | 2021 | |
| Allergan, INC. | $131.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $130.20 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $127.05 | 2019-2021 | |
| Amgen INC. | $111.41 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $108.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.44 | 2021-2022 | |
| Mylan Specialty L.P. | $84.74 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.29 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.41 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $64.15 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $56.48 | 2021 | |
| Lilly USA, LLC | $51.93 | 2021-2024 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $47.16 | 2020-2021 | |
| Glaxosmithkline, LLC. | $41.99 | 2019-2020 | |
| Promius Pharma LLC | $26.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.43 | 2019-2020 | |
| Alkermes, INC. | $23.09 | 2019 | |
| Exact Sciences Corporation | $18.65 | 2023 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $16.86 | 2024 | |
| Ardelyx, INC. | $16.11 | 2024 | Ibsrela |
| Amneal Pharmaceuticals LLC | $15.48 | 2022 | |
| Shire North American Group INC | $15.03 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.82 | 2019 | |
| Bausch Health US, LLC | $12.30 | 2019 | |
| Biodelivery Sciences International, INC. | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvey Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.